Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × regorafenib × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 45 Neoplasms 13 Neoplasm Metastasis 12 Gastrointestinal Stromal Tumors 8 Glioblastoma 5 Colonic Neoplasms 5 Carcinoma, Hepatocellular 5 Stomach Neoplasms 3 Sarcoma 3 Ovarian Neoplasms 3 Rhabdomyosarcoma 2 Rectal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Liver Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Neoplasms 2 Colorectal Cancer Metastatic 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Advanced Cancer 2 Wilms Tumor 1 Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Solid Tumor 1 Sarcoma, Ewing 1 Renal Insufficiency 1

Interventions

Gemcitabine 26 Fluorouracil 23 Oxaliplatin 19 Cisplatin 18 Leucovorin 15 Bevacizumab 14 Paclitaxel 12 130-nm albumin-bound paclitaxel 12 Capecitabine 11 Docetaxel 10 Albumin-Bound Paclitaxel 10 Irinotecan 9 Carboplatin 9 pembrolizumab 6 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Cyclophosphamide 6 Ramucirumab 5 Erlotinib Hydrochloride 5 Trastuzumab 4 Everolimus 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3 Ipilimumab 3 Gefitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929616 2019-06-25

RegARd-C

Jules Bordet Institute

Phase 2 Completed

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡